JP Morgan Chase
AGIO icon

JP Morgan Chase’s Agios Pharmaceuticals AGIO Stock Holding History

JP Morgan Chase’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$897K Hold
30,300
– – ﹤0.01% 4673
2025
Q4 		$825K Buy
30,300
+11,900
+65% +$418K ﹤0.01% 4727
2025
Q3 		$739K Hold
18,400
– – ﹤0.01% 4798
2025
Q2 		$612K Buy
+18,400
New +$558K ﹤0.01% 4669
2021
Q3 		– Sell
-30,700
Closed -$1.69M – 6450
2021
Q2 		$1.69M Hold
30,700
– – ﹤0.01% 3912
2021
Q1 		$1.58M Sell
30,700
-31,400
-51% -$1.56M ﹤0.01% 3885
2020
Q4 		$2.69M Buy
62,100
+25,700
+71% +$1.02M ﹤0.01% 3270
2020
Q3 		$1.25M Sell
36,400
-8,600
-19% -$377K ﹤0.01% 3518
2020
Q2 		$2.41M Sell
45,000
-30,000
-40% -$1.39M ﹤0.01% 2982
2020
Q1 		$2.66M Buy
75,000
+50,000
+200% +$2.31M ﹤0.01% 2755
2019
Q4 		$1.19M Hold
25,000
– – ﹤0.01% 3728
2019
Q3 		$810K Buy
+25,000
New +$1.03M ﹤0.01% 3947
2018
Q4 		– Sell
-30,000
Closed -$2.31M – 5663
2018
Q3 		$2.31M Buy
+30,000
New +$2.41M ﹤0.01% 3353

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

JP Morgan Chase's AGIO Position: Q1 2026 in Review

JP Morgan Chase reduced its Agios Pharmaceuticals (AGIO) stake by 40% in Q1 2026, selling an estimated $2.84M and leaving 151,558 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3418.

JP Morgan Chase first reported a position in AGIO in Q3 2013 and has held it in 51 quarters since. The position peaked at $284M in Q2 2021. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • JP Morgan Chase held 151,558 shares of Agios Pharmaceuticals worth $4.49M as of Q1 2026.
  • JP Morgan Chase sold 100,219 Agios Pharmaceuticals shares in Q1 2026, an estimated $2.84M.
  • Agios Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3418 holding.
  • JP Morgan Chase first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
  • JP Morgan Chase's Agios Pharmaceuticals position peaked at $284M in Q2 2021.
  • 233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.